Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Richter Transformation’

We are big fans of the American Society of Hematology (ASH) annual meeting, it certainly is the global meeting for hematology! The quality of research presented is very high; it’s where you see groundbreaking and practice changing hematology data, sometimes from unexpected sources.

Last year brought us long lines, crowded escalators, and jam packed halls, especially for the niche sessions.  It’s hard to imagine any of these in pandemic these days, especially if someone were to start suddenly coughing and sneezing in the seat behind…

A bit of nostalgia from ASH19: Up close and personal

Will we all be together again for #ASH21? According to virology experts, we’ll need 70% of people (around the world, not just in one country!) to have had a COVID-19 vaccine before we can lower our masks and do away with social distancing.

Even if 70% of health care professionals are vaccinated, a not unrealistic figure if you look at the flu vaccine uptake, going to an in-person meeting means you still have to navigate the cumulative risk associated with airports, flights, hotels, ground transportation, plus eating out in an urban environment where the very visible inequality that exists in America means it is highly unlikely everyone you may come into contact with, directly or indirectly, will be vaccinated.

There’s also the uncertainty of how durable any vaccination is, raising the prospect that any COVID-19 vaccination is unlikely to be “once and done” – will we all need boosts six months later? The logistics for all of this are just mind blowing.

Despite the exhortations from ASH leadership that they look forward to seeing us in Georgia next year at #ASH21 and we should all plan to be there, as things stand we don’t recommend booking your flights to Atlanta and #ASH21 just yet.

BSB expects 2021 to be another year of virtual meetings!

Meanwhile, on with the business of exploring the emerging data from ASH 20.

In this latest post, we are highlighting a few of the presentations that caught our attention on the various bispecific antibodies and T cell engagers in advanced lymphomas and multiple myeloma…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH meeting — including our daily highlights coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

The abstracts (apart from the late-breakers) for the 2016 annual meeting of the American Society of Hematology (Twitter #ASH16) went live at 9am ET today. Link to 2016 ASH Abstracts.

ASH16 takes place in San Diego from December 3-6.

View of San Diego from ASH 2011In this initial post, I’m sharing my first impressions of what may be some hotly contested trials at ASH16 in San Diego, as well as a few intriguing abstracts with combination data that caught my attention.

With over 3,000 oral and poster presentations, all typically of a high quality, this by post by definition, is a highly subjective one.

After we’ve had more time to process the data, further ASH16 Previews will roll out over the next few weeks highlighting more key abstracts to watch out for by tumour type or treatment modality.

In-depth commentary and analysis will follow after we’ve heard or seen the data presented at the meeting.

I’ll be flying to ASH from the EORTC-NCI-AACR Molecular Targets meeting. Do say “hello” if you have plans to be in Munich or San Diego.

Subscribers can login to read more insights or you can purchase access…

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!